| Budget Amount *help |
¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
|---|
| Outline of Final Research Achievements |
Though the treatment for severe Henoch-Schonlein purpura nephritis (HSPN) is not established, limited experience with cyclosporin A (CsA) shows reduction of proteinuria. However, the mechanism of anti-proteinuric effect of CsA in HSPN remains unknown. We wonder whether CsA directly acts on podocytes via non-immunological effect and exerts anti-proteinuric effect in severe HSPN.
To explore the mechanism of action of CsA, we evaluated urinary levels of mRNA of synaptopodin and podocin using quantitative RT-polymerase chain reaction and compared them before and after CsA administration. Administration of CsA significantly increased urinary mRNA of synaptopodin and podocin. We postulate that CsA exerts anti-proteinuric effect via action on podocytes via non-immunological mechanism in HSPN.
|
